ENDRA Life Sciences announces 1-for-50 reverse stock split to regain Nasdaq bid price compliance

ENDRA Life Sciences Inc.

Reverse split effective Aug 20, 2024; shares outstanding drop from ~72.4M to ~1.4M.
Authorized shares reduced from 1B to 20M; fractional shares are rounded up to whole shares.
Split intended to raise bid price above $1.00 to meet Nasdaq continued listing requirement.
New CUSIP 29273B 401; common stock continues trading under NDRA on Nasdaq.
Board set ratio on Aug 8 after stockholder authorization at Aug 6 annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.